Primary result of the efficacy and tolerance of gefitinib in advanced non-small cell lung cancer patients with brain metastasis

Medicine and Dentistry

• Gefitinib 100%
• Non Small Cell Lung Cancer 85%
• Brain Metastasis 71%
• Patient 71%
• Inpatient 42%
• Diseases 28%
• Spontaneous Remission 28%
• Irradiation 28%
• Survival 28%
• Targeted Therapy 28%
• Follow up 14%
• Disease Exacerbation 14%
• Adverse Event 14%
• Epidermal Growth Factor Receptor Kinase Inhibitor 14%
• Exanthem 14%
• Antineoplastic Activity 14%
• Diarrhea 14%
• Progressive Disease 14%
• Smoking 14%
• Therapeutic Procedure 14%
• Gender 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Gefitinib 100%
• Non Small Cell Lung Cancer 85%
• Brain Metastasis 71%
• Randomized Clinical Trial 42%
• Diseases 28%
• Remission 28%
• Irradiation 28%
• Brain Injury 28%
• Survival 28%
• Disease Exacerbation 14%
• Adverse Event 14%
• Diarrhea 14%
• Rash 14%
• Epidermal Growth Factor Receptor Kinase Inhibitor 14%

Biochemistry, Genetics and Molecular Biology

• Gefitinib 100%
• Survival 28%
• Receptor Tyrosine Kinase Inhibitors 14%
• Epidermal Growth Factor Receptor 14%
• Antineoplastic Activity 14%
• Smoking 14%
• Time 14%
• Gender 14%